Skip to main content

Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin.

Publication ,  Journal Article
Hockenberry, MJ; Hooke, MC; Gregurich, M; McCarthy, K
Published in: Journal of pediatric hematology/oncology
September 2009

Fatigue is the most frequent symptom experienced by children/adolescents with cancer. One mechanism contributing to cancer-related fatigue involves abnormalities in adenosine triphosphate synthesis caused by carnitine deficiency. The purpose of this study was to examine fatigue and carnitine in children/adolescents before and after ifosfamide, cisplatin, or doxorubicin chemotherapy. Sixty-seven patients from 2 children's cancer centers participated. Fatigue and carnitine measures were obtained before chemotherapy and a week later. Newly diagnosed children/adolescents had significantly higher free (P=0.018) and total carnitine levels (P=0.017) compared with those who received prior chemotherapy. There was a significant increase in free and total carnitine levels after treatment for patients receiving doxorubicin than patients receiving cisplatin or ifosfamide. Increased fatigue and decreased carnitine were significantly correlated a week after chemotherapy in children/adolescents who had received prior chemotherapy. Increased carnitine in newly diagnosed patients is likely associated with rapid tissue release into the bloodstream, replacing carnitine lost by chemotherapy metabolism. Decreased carnitine and increased fatigue occurred after 1 to 2 courses of chemotherapy. This study provides support for a relationship between carnitine and fatigue in children/adolescents with cancer.

Duke Scholars

Published In

Journal of pediatric hematology/oncology

DOI

EISSN

1536-3678

ISSN

1077-4114

Publication Date

September 2009

Volume

31

Issue

9

Start / End Page

664 / 669

Related Subject Headings

  • Surveys and Questionnaires
  • Severity of Illness Index
  • Oncology & Carcinogenesis
  • Neoplasms
  • Male
  • Ifosfamide
  • Humans
  • Female
  • Fatigue
  • Energy Metabolism
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Hockenberry, M. J., Hooke, M. C., Gregurich, M., & McCarthy, K. (2009). Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin. Journal of Pediatric Hematology/Oncology, 31(9), 664–669. https://doi.org/10.1097/mph.0b013e3181b259a7
Hockenberry, Marilyn J., Mary C. Hooke, MaryAnn Gregurich, and Kathy McCarthy. “Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin.Journal of Pediatric Hematology/Oncology 31, no. 9 (September 2009): 664–69. https://doi.org/10.1097/mph.0b013e3181b259a7.
Hockenberry MJ, Hooke MC, Gregurich M, McCarthy K. Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin. Journal of pediatric hematology/oncology. 2009 Sep;31(9):664–9.
Hockenberry, Marilyn J., et al. “Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin.Journal of Pediatric Hematology/Oncology, vol. 31, no. 9, Sept. 2009, pp. 664–69. Epmc, doi:10.1097/mph.0b013e3181b259a7.
Hockenberry MJ, Hooke MC, Gregurich M, McCarthy K. Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin. Journal of pediatric hematology/oncology. 2009 Sep;31(9):664–669.

Published In

Journal of pediatric hematology/oncology

DOI

EISSN

1536-3678

ISSN

1077-4114

Publication Date

September 2009

Volume

31

Issue

9

Start / End Page

664 / 669

Related Subject Headings

  • Surveys and Questionnaires
  • Severity of Illness Index
  • Oncology & Carcinogenesis
  • Neoplasms
  • Male
  • Ifosfamide
  • Humans
  • Female
  • Fatigue
  • Energy Metabolism